175 related articles for article (PubMed ID: 38400680)
1. Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study.
Zhong WJ; Lin JA; Wu CY; Wang J; Chen JX; Zheng H; Ye K
Cancer Med; 2024 Feb; 13(3):e7006. PubMed ID: 38400680
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
Li N; Li Z; Fu Q; Zhang B; Zhang J; Wan XB; Lu CM; Wang JB; Deng WY; Ma YJ; Bie LY; Wang MY; Li J; Xia QX; Wei C; Luo SX
Int J Surg; 2024 Apr; 110(4):2071-2084. PubMed ID: 38320099
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
4. The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction.
Tang Z; Wang Y; Liu D; Wang X; Xu C; Yu Y; Cui Y; Tang C; Li Q; Sun J; Zhang Q; Ji Y; Ma G; Li H; Shen Z; Shen K; Zheng R; Hou Z; Liu T; Wang J; Sun Y
Nat Commun; 2022 Nov; 13(1):6807. PubMed ID: 36357415
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
Yang Y; Zhang J; Meng H; Ling X; Wang X; Xin Y; Jiang H; Zhang L; Fang C; Liang H; Ma J; Zhu J
Int J Surg; 2024 Mar; 110(3):1430-1440. PubMed ID: 38051925
[TBL] [Abstract][Full Text] [Related]
6. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
8. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.
Tang Z; Wang Y; Yu Y; Cui Y; Liang L; Xu C; Shen Z; Shen K; Wang X; Liu T; Sun Y
BMC Med; 2022 Apr; 20(1):107. PubMed ID: 35382819
[TBL] [Abstract][Full Text] [Related]
10. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
12. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
[TBL] [Abstract][Full Text] [Related]
13. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
14. Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.
Iwatsuki M; Orita H; Kobayashi K; Hidaka S; Arigami T; Kusumoto T; Satake H; Oki E; Tsutsumi S; Tobimatsu K; Shimokawa M; Saeki H; Makiyama A; Baba H; Mori M
Gastric Cancer; 2022 Jan; 25(1):180-187. PubMed ID: 34379229
[TBL] [Abstract][Full Text] [Related]
15. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol.
Wu L; Yan H; Qin Y; Huang M; Wang T; Jin Q; Wei W
BMJ Open; 2024 Feb; 14(2):e075696. PubMed ID: 38341203
[TBL] [Abstract][Full Text] [Related]
16. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial.
Shi J; Li N; Tang Y; Jiang L; Yang L; Wang S; Song Y; Liu Y; Fang H; Lu N; Qi S; Chen B; Li Z; Liu S; Wang J; Wang W; Zhu S; Yang J; Li Y; Zhao D; Jin J
BMC Gastroenterol; 2022 Jul; 22(1):359. PubMed ID: 35902798
[TBL] [Abstract][Full Text] [Related]
17. A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.
Shi JM; Li N; Jiang LM; Yang L; Wang SL; Song YW; Liu YP; Fang H; Lu NN; Qi SN; Chen B; Li YX; Zhao DB; Tang Y; Jin J
Sci Rep; 2024 Mar; 14(1):7522. PubMed ID: 38553594
[TBL] [Abstract][Full Text] [Related]
18. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y; Li D; Zhuang J; Li Z; Xia Q; Li Z; Yu J; Wang J; Zhang Y; Li K; Xu S; Li S; Ma P; Cao Y; Liu C; Xu C; Liu Z; Wei J; Zhang C; Qiao L; Gao X; Hou Z; Liu C; Zheng R; Wang D; Liu Y
Clin Transl Med; 2024 May; 14(5):e1674. PubMed ID: 38685486
[TBL] [Abstract][Full Text] [Related]
20. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
